Sangamo Therapeutics, Inc. (SGMO)

0.5558 +0.0338 (+6.48%) 收市：04:00PM EDT

Sangamo Therapeutics, Inc.

501 Canal Blvd
Richmond, CA 94804
United States
510-970-6000
https://www.sangamo.com

版塊: Healthcare
行業: Biotechnology
全職員工: 405

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.	CEO, President & Director	722.67k	無	1963
Dr. Nathalie Dubois-Stringfellow Ph.D.	Senior VP & Chief Development Officer	459.9k	無	1962
Ms. Amy Pooler Ph.D.	Head of Research	無	無	無
Mr. Gregory Davis Ph.D.	Head of Technology	無	無	無
Ms. Aron Feingold	Head of Corporate Communications & Investor Relations Officer	無	無	無
Mr. Scott B. Willoughby	Senior VP, General Counsel & Corporate Secretary	無	無	1975
Phillip Ramsey	Head of Technical Operations	無	無	無
Ms. Stephanie J. Seiler CLP	Head of Business Development & Alliance Management	無	無	無
Mr. David Ojala	Scientist II - Discovery & Translational Research	無	無	無
Louise Wilkie	Vice President of Investor Relations & Corporate Communications	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

公司管治

截至 2024年5月1日 止，Sangamo Therapeutics, Inc. 的 ISS 管治質素評分為 3。 Pillar 分數正在審核中：6；董事會：1；股東權利：2；現金賠償：6。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。